Vol. XXXVII No. 2
Editor: Heather J. Stalker, M.Sc.
Director: Megan Boothe, M.D
By: Julia Piermattei, BS Genetic Counseling Student Medical University of South Carolina
Introduction:
Cockayne Syndrome (CS) is a rare autosomal recessive disorder characterized by small size, delayed growth and development, distinctive physical features, and neurological abnormalities including intellectual disability. CS affects males and females equally and has been diagnosed in individuals across different racial/ethnic backgrounds. The incidence of CS is estimated at 1 in every 250,000 live births. There are three types of CS that vary based on age of onset and severity.
- Type 1 – classical or moderate form is most common type of CS where symptoms start around 2 years of age.
- Type 2 – congenital form is the most severe type where symptoms start at birth or prenatally.
- Overlap with cerebrooculofaciskeletal (COFS) syndrome aka the “prenatal form of CS”.
- Type 3 – late onset: symptoms start later in childhood with less severe symptoms.
Clinical Features:
CS affects many different organ systems. These symptoms include:
- Growth failure (prenatally and postnatally) and distinctive facial features including sunken eyes, microcephaly, prominent and high set ears, and a beaked nose.
- Neurological abnormalities including developmental delays and intellectual disabilities, spasticity, and nerve pain.
- Musculoskeletal issues including abnormal gait, muscle weakness and stiffness, joint problems, and longer limbs.
- Photosensitivity in skin, hair, and nails, leading to lighter coloration and easy burning of the skin and thin hair.
- Dental cavities and smaller permanent teeth.
- Vision issues including: cataracts, pigmentary retinopathy, and optic atrophy.
- Progressive hearing loss.
- Renal failure.
- Cardiac hypertension and cardiomyopathy.
- Gastroesophageal reflux
- Decreased production of sweat, tears, and saliva
- Endocrine dysfunction including hypogonadism in males
Genetics:
CS is caused by mutation or changes in either the ERCC6 or ERCC8 gene. ERCC6 is associated with CS type II while ERCC8 is associated with CS type I. These genes are responsible for repairing damaged DNA due to sunlight and normal cell processes. Faulty DNA repair causes photosensitivity and other problems in individuals with CS. It is important to note that CS is not associated with higher risk of cancer.
Inheritance:
CS is inherited in an autosomal recessive manner meaning it takes both copies of either the ERCC6 or the ERCC8 gene to be affected to have symptoms of CS. We all have two copies of our ERCC6 gene and our ERCC8 gene. For an individual to have CS, both parents are carriers of CS as each parent would carry one copy of the mutation. Amongst parents who are both carriers of CS, there is a 25% chance, or 1 in 4 chances, to have a child with CS. Carriers of CS do not have any symptoms of the condition. Genetic counseling is beneficial for patients and families in discussing CS inheritance and recurrence risks for family planning.

Diagnosis:
Molecular genetic testing is needed to confirm a diagnosis of CS. Genetic testing can be performed prenatally through amniocentesis or chorionic villus sampling and performed after birth through ERCC6/ERCC8 gene testing, multi-gene panel testing, or whole exome/genome sequencing. Patients should undergo evaluations and testing in other specialties to rule out other diagnoses such as audiology, ophthalmology, dermatology, neurology, and endocrinology. There are several conditions that overlap with similar features as CS, which is why undergoing evaluations and testing in other specialties is crucial in eliminating other diagnoses.
Management and Treatment:
There is no cure for CS, but supportive care can greatly improve comfort and quality of life. Palliative care is an option of care, especially for those with more severe types of CS. Regular evaluations to monitor for hearing loss, eye problems, blood sugar and pressure, liver/renal function, dental cavities, and progression of neurological issues is beneficial for patients. No treatments have been identified that could slow or halt progression of CS. The list of potential care needs is as followed:
- Feeding Assistance with feeding tube as needed for malnutrition.
- Early intervention programs to access physical, speech, feeding, and occupational therapies and other infant/early childhood support services.
- Physical therapy to improve muscle and joint functions. Consider use of movement assistance equipment such as wheelchairs, walkers, etc.
- Occupational therapy to improve fine motor skills.
- Ocular treatments such as surgical correction of cataracts.
- Audiology therapies including hearing aids.
- Skin protection from UV light exposure at all times when outdoors. Recommendations include wearing sunscreen with SPF 50 or greater, wearing broad-brimmed hats, protective eyewear, and UV-resistant clothing.
- Medications: Use of metronidazole should be avoided for risks of severe liver inflammation.
Family Resources:
- The Share and Care Cockayne Syndrome Network
Email: cockaynesyndrome@gmail.com - The Cockayne Syndrome Foundation
Phone: (518) 578-8683
Email: info@thecockaynesyndromefoundation.org
References:
- Ajoy C. Karikkineth, Morten Scheibye-Knudsen, Elayne Fivenson, Deborah L. Croteau, Vilhelm A. Bohr, Cockayne syndrome: Clinical features, model systems and pathways, Ageing Research Reviews, Volume 33, 2017, Pages 3-17, ISSN 1568-1637, https://doi.org/10.1016/j.arr.2016.08.002.
- Hafsi W, Saleh HM. Cockayne Syndrome. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525998/
- Laugel V. Cockayne Syndrome. 2000 Dec 28 [Updated 2024 Aug 29]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 -2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1342/